Last reviewed · How we verify
AIT Tablet
AIT Tablet is an allergen immunotherapy tablet that desensitizes the immune system to specific allergens through gradual oral exposure.
AIT Tablet is an allergen immunotherapy tablet that desensitizes the immune system to specific allergens through gradual oral exposure. Used for Allergic rhinitis and/or allergic asthma caused by specific allergens (e.g., grass pollen, tree pollen, dust mites, depending on formulation).
At a glance
| Generic name | AIT Tablet |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Drug class | Allergen immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
AIT (Allergen Immunotherapy) tablets work by delivering small, increasing doses of allergen extract under the tongue, which promotes immune tolerance through regulatory T cell induction and shift from Th2 to Th1/Treg responses. This sublingual route allows for local immune modulation in oral mucosa-associated lymphoid tissue, reducing allergic symptoms upon natural allergen exposure. The tablet formulation provides a convenient, non-injection alternative to traditional subcutaneous immunotherapy.
Approved indications
- Allergic rhinitis and/or allergic asthma caused by specific allergens (exact allergen depends on formulation)
Common side effects
- Oral pruritus
- Throat irritation
- Mouth edema
- Ear pruritus
- Gastrointestinal symptoms
Key clinical trials
- Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy. (PHASE4)
- Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab (PHASE3)
- Vestibular Versus Sublingual Route of AIT Tablets (PHASE4)
- The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma (PHASE4)
- N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
- Criteria Used by Health Professionals on the Selection of Allergen Immunotherapy in Real Clinical Practice
- Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study (PHASE2)
- A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AIT Tablet CI brief — competitive landscape report
- AIT Tablet updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI